Medical Devices Reimbursement Market Report Scope & Overview:

The Medical Devices Reimbursement Market was valued at USD 667.31 Billion in 2025 and is expected to reach USD 1,397.24 Billion by 2035, growing at a CAGR of 7.67% from 2026–2035.

The medical devices reimbursement market continues to expand on the back of rising healthcare spending, growing adoption of advanced medical technologies, and increasing prevalence of chronic illness worldwide. Supportive reimbursement policies across developed economies continue to encourage healthcare providers to incorporate sophisticated medical devices into standard care pathways, while the broader industry shift toward value-based care and expanded access to medical services continues to sustain demand. As governments and private insurers extend coverage for an increasingly complex range of medical technologies, from smart implants to robotic surgical equipment to wearable health monitors, the reimbursement infrastructure required to support this technology adoption continues to grow in scale and sophistication.

According to research published in the National Center for Biotechnology Information database, incentives and regulations within the U.S. healthcare system have created uneven uptake of medical technologies, resulting in both underutilization of effective, cost-saving innovations and overutilization of technologies that are less clinically or economically effective. Reimbursement models, professional incentives, legal frameworks, and patient expectations all continue to shape medical device reimbursement dynamics across the U.S. healthcare system.

Market Size and Forecast

• Market Size in 2026E: USD 718.49 Billion

• Market Size by 2035: USD 1,397.24 Billion

• CAGR: 7.67% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get More Information On Medical Devices Reimbursement Market - Request Free Sample Report

Medical Devices Reimbursement Market Trends

• Payers are increasingly adopting value-based care reimbursement models that tie medical device coverage decisions to demonstrated clinical outcomes rather than device category alone.

• Health IT system improvements and administrative digitization are reducing claim processing timelines and improving reimbursement accuracy across both public and private payer systems.

• Regulatory bodies including CMS and the FDA are pursuing closer alignment between device approval pathways and coverage decisions to accelerate patient access to breakthrough medical technologies.

• Private payers are expanding device-specific coverage plans in response to rising chronic disease prevalence and growing adoption of advanced diagnostic and therapeutic technologies.

• Emerging markets are implementing structured reimbursement frameworks for medical devices as governments prioritize expanded insurance coverage and reduced out-of-pocket healthcare expenditure.

U.S. Medical Devices Reimbursement Market Outlook

The U.S. Medical Devices Reimbursement Market was valued at approximately USD 284.26 Billion in 2025 and is expected to reach approximately USD 583.70 Billion by 2035, growing at a CAGR of approximately 7.46%.

The United States is at the forefront of the North America medical devices reimbursement market owing to a highly developed healthcare system, strong reimbursement policy, and high use of modern technology in the field of medicine. The United States has an advanced third party payment system in place, which includes public payment plans such as Medicare and Medicaid, as well as private payers. This helps in enabling smooth reimbursement of medical devices. Further, regulatory clarity from organizations like Centers for Medicare & Medicaid Services continues to drive innovation and quicker decision-making for new devices' reimbursement, while high healthcare expenditure and aging population are additional drivers of demand in this market.

On November 1, 2024, the Centers for Medicare & Medicaid Services issued the final rule regarding CY 2025 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System that creates separate payment for drugs and devices classified as non-opioid therapies for pain relief in the settings of hospitals and ambulatory surgical centers starting on January 1, 2025. The rule is an example of how regulatory support continues to provide avenues for reimbursement of clinically proven medical devices that help address public health priorities.

Medical Devices Reimbursement Market Segmentation Analysis

• By Claim, the Underpaid segment dominated the Medical Devices Reimbursement Market with an 82.10% revenue share in 2024, while the Fully Paid segment is expected to demonstrate significant growth.

• By Payer, the Public Payers segment dominated the Medical Devices Reimbursement Market with a 68.09% revenue share in 2024, while the Private Payers segment is the fastest growing with a CAGR of approximately 7.82%.

• By Service Provider, the Physician Office segment dominated the Medical Devices Reimbursement Market with a 48.04% revenue share in 2024, while the Hospitals segment is expected to demonstrate the fastest growth.

By Claim, underpaid claims dominate, fully paid claims show significant growth potential

Underpaid claims were responsible for the highest percentage of revenue generated in 2025, which was 82.10%, owing to inefficiencies in the payment system and the difficulty associated with the medical billing process in national healthcare markets. Payment to healthcare practitioners is often made in a partial manner owing to claim rejections or denials, coding problems, or coverage limits from insurance companies in markets where there are fluctuating reimbursement policies.

Fully paid claims will show strong growth in the projected period because governments and private payers will focus on streamlining and efficiency in the payment process due to increasing emphasis on reducing cost and improving transparency. The pressure for financial sustainability and adoption of value-based care models will compel payers to improve claim processing accuracy.

By Payer, public payers lead the market, private payers register the fastest growth

The public payers category held the highest market revenue share in 2025, accounting for 68.09%, owing to the high availability of medical devices under government-funded healthcare programs, especially in developed countries. Medicare and Medicaid of the US, and other national health services of the EU and elsewhere, cater to a significant share of medical device reimbursement through standardized policies that ensure wide device coverage and payment arrangements.

Private payers are expected to experience the most rapid growth rate during the forecast period at around 7.82% CAGR, as private health insurers expand their portfolio of coverage due to high healthcare demands and escalating costs of treatment of chronic diseases. With the increasing prevalence of private health insurance in emerging countries and innovations in medical devices, private payers are transforming into device-oriented reimbursement organizations.

By Service Provider, physician offices lead current demand, hospitals register the fastest growth

In 2025, physician office clinics held the maximum market share among service providers, with 48.04%, owing to their importance in chronic disease treatment and outpatient services, which require a lot of medical devices. Usually, physicians' clinics act as the first point of contact for patients seeking reimbursement through devices.

Of all the different categories of service providers, hospitals are expected to witness the highest rate of growth owing to the increased usage of advanced medical devices that have become costly due to their complexity. There is an increased usage of advanced medical devices like robotic surgical devices and intelligent monitoring devices in the hospitals.

Regional Analysis:

North America Medical Devices Reimbursement Market Insights

The North American region dominated the medical device reimbursement market in 2024, with its market share accounting for 46.23%. This is facilitated by the presence of a well-developed healthcare system, advanced reimbursement policies, high penetration rate of insurance plans, and comprehensive medical device reimbursement infrastructure. The US healthcare system has a very well-developed third-party payer system that facilitates reimbursement efficiently through public and private payers.

Clear regulations provided by various regulatory organizations, such as the Centers for Medicare & Medicaid Services, have been playing a key role in driving innovation and coverage of medical devices. The high per capita health expenditure, along with the aging population, has been boosting the regional market dominance further.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Asia Pacific Medical Devices Reimbursement Market Insights

Asia Pacific is the fastest-growing regional market, with a projected CAGR of 8.66% through the forecast period, driven by expanding healthcare infrastructure, growing government initiatives to increase insurance coverage, and rising demand for advanced medical devices among an expanding middle class. China, India, and Japan continue to implement organized reimbursement policies aimed at managing out-of-pocket healthcare expenditure and improving access to health technologies.

The growing prevalence of chronic conditions and the broader industry transition toward value-based care continue to encourage government investment in reimbursement schemes that promote long-term care access and device affordability. These combined trends collectively position Asia Pacific as a central growth driver for the global market.

Europe Medical Devices Reimbursement Market Insights

Germany leads the European medical devices reimbursement market, supported by a robust statutory health insurance system covering more than 90% of the population. The country's centralized health system maintains well-functioning reimbursement channels for a broad range of medical devices, predominantly administered through publicly funded sickness funds.

Germany's institutionalized appraisal system, administered by the Federal Joint Committee, evaluates medical technologies based on clinical effectiveness and cost-effectiveness for coverage determination, a structured framework that continues to position Germany as a leading market for medical device reimbursement policy within the broader European region.

MEA & Latin America Medical Devices Reimbursement Market Insights

Latin America and the Middle East and Africa are witnessing moderate growth in the medical devices reimbursement market over the forecast period, largely constrained by limited healthcare infrastructure, reduced insurance penetration, and fragmented reimbursement systems across the region. Certain countries within these regions are gradually expanding healthcare coverage and integrating structured reimbursement systems, though growth remains uneven across individual national markets.

Saudi Arabia and Brazil represent the leading national markets within their respective regions, supported by ongoing healthcare infrastructure investment and gradually expanding insurance coverage. Continued government investment in healthcare modernization is expected to support incremental market growth across both regions throughout the forecast period.

Growth Drivers: Growing adoption of sophisticated medical technologies sustains reimbursement demand

The continuous development in medical technology like smart implants, robotic surgery tools, and wearable healthcare devices is continually pushing physicians to use advanced technologies for diagnosis, monitoring, and treatment of their patients. These technologies come at relatively higher prices, and hence there is a need for reimbursement in order to keep their prices affordable.

There are ongoing government policies that are facilitating this trend through such examples as the U.S. Medicare and Medicaid program that covers the cost of medical devices that are being used widely by older and poor populations, and there is increasing device reimbursement through the health insurance schemes in Europe.

Restraints: Complex and fragmented reimbursement frameworks constrain market growth

Fragmentation and complexities in the reimbursement system, which differ greatly based on payers and geographies, serve as the key limitations to the growth of medical devices reimbursement market. Reimbursement for medical devices is generally very diverse, differing widely based on the type of the device, the place of use, and the payer’s reimbursement policy.

These diversities lead to prolonged decision-making and difficulties for manufacturers in their plans to penetrate the market. Changing regulations and coding standards create additional hurdles that delay the process of reimbursement.

Opportunities: Expanding insurance coverage and health technology adoption create growth potential

Further growth and development of the government healthcare program and insurance coverage projects present a large potential for growth of the medical device reimbursement market. The development of projects such as India's Ayushman Bharat project, Heal-in-India project, and Start-up Mission project helps to create an environment conducive for investments and thus attracts private sector investment in the broader healthcare sector.

The application of innovative technologies such as Internet of Things (IoT) enabled wearables, artificial intelligence and blockchain technology in healthcare services further drives the transition towards decentralized and technology-driven healthcare services management system. The adoption of smart wearable devices is increasing and hence there is a great opportunity for growth in the reimbursement of these innovative devices category.

Recent Developments:

• 2024: On November 1, 2024, the Centers for Medicare & Medicaid Services finalized its CY 2025 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule, establishing separate payment for non-opioid pain treatment devices effective January 1, 2025.

• 2025: In February 2025, the Centers for Medicare & Medicaid Services issued a National Coverage Decision establishing Medicare coverage for implantable pulmonary artery pressure sensors used in the treatment of heart failure, expanding access to advanced cardiac monitoring technology for qualifying beneficiaries.

• 2025: In March 2025, Optum Rx announced a shift to a cost-based reimbursement model aligning payments with actual pharmacy expenses, supporting over 24,000 independent pharmacies, with full implementation targeted for January 2028.

Medical Devices Reimbursement Market Key Players

• UnitedHealth Group

• Allianz SE

• Nippon Life Insurance Company

• Aviva plc

• WellCare Health Plans, Inc.

• Aetna Inc.

• BNP Paribas

• Cigna Healthcare

• Humana Inc.

• CVS Health Corporation

• Medtronic plc

• Anthem, Inc. (Elevance Health)

• Molina Healthcare, Inc.

• Centene Corporation

• Kaiser Permanente

• AXA S.A.

• MetLife, Inc.

• Zurich Insurance Group

• Prudential Financial, Inc.

• Optum Rx (UnitedHealth Group)

Medical Devices Reimbursement Market Report Scope: